Pharma News
Biocon and Biomm forge alliance to bring semaglutide diabetes treatment to Brazil
By mid-April 2024, India-based Biocon Biologics signed an exclusive licensing and supply agreement that will allow Brazil’s Biomm SA to commercialise semaglutide, which is used to control type-2 diabetes in adults and has been repurposed for obesity management.
Klinge–MS Pharma and Teva–mAbxience biosimilars licence agreements
In May 2024, Klinge Biopharma announced an exclusive licensing and supply agreement with MS Pharma for FYB203 commercialization in the Middle East and North Africa (MENA) region. Previously, in April 2024, mAbxience and Teva Pharmaceuticals signed a strategic licensing agreement for a biosimilar candidate for oncology treatment.
Celltrion wins Peruvian public tenders for biosimilar infliximab and trastuzumab
In early May 2024, Celltrion reported that two of its biosimilar products, infliximab and trastuzumab, won the public tender in Peru, further expanding their prescription availability in Peru and solidifying their position in the broader Latin American pharmaceutical market.
Bio-Thera and SteinCares sign agreement to market two biosimilars in LATAM
Bio-Thera Solutions (Bio-Thera) announced in March 2024 a licensing agreement with SteinCares to market two biosimilars in Brazil and the rest of the region.
Formycon launches biosimilar ranibizumab Ravegza in Saudi, Gedeon Richter invests
In March 2024, Formycon and MS Pharma announced that their FYB201/ranibizumab Ravegza, a biosimilar to Lucentis, has received marketing authorization from the Saudi Food and Drug Authority.
mAbxience and Biosidus sign an agreement to manufacture Agalsidase Beta
mAbxience announced in February 2024 a pivotal agreement with Biosidus to manufacture Agalsidase Beta. This joint effort is expected to have a significant impact on the lives of patients affected by Fabry disease.
Biosimilars lawsuits and settlement updates for Regeneron and Alvotech
In January 2024, Regeneron filed a lawsuit against Amgen in the federal court in Los Angeles, alleging Amgen's proposed biosimilar of Regeneron's Eylea (aflibercept) violates patent rights. Additionally, in February 2024, Iceland-based Alvotech announced the anticipated global market entry dates for AVT04, a ustekinumab biosimilar to Stelara, following its settlement with Johnson & Johnson.
The journey of Pectuna pertuzumab follow-on biological in Iran
Pertuzumab is a monoclonal antibody (mAb) that inhibits the dimerization of human epidermal growth factor receptor 2 (HER2) with other HER receptors, which prevents them from signalling in ways that promote cell growth and proliferation. It is a pivotal therapeutic in oncology, targeting the overexpressed HER2 protein, particularly in breast cancer [1].
Sandoz US acquisition of ranibizumab biosimilar from Coherus
On 22 January 2024, it was announced that in the US, Sandoz will acquire ranibizumab biosimilar Cimerli (ranibizumab) from Coherus BioSciences.
Fiocruz and Pfizer sign agreement for generic of Xeljanz
Farmanguinhos/Fiocruz, the Institute of Drug Technology in Brazil, has signed a technology transfer agreement with Pfizer Brazil for the manufacturing of tofacitinib citrate, a generic counterpart to Xeljanz.
